News
Your search is "" and there are 2483 results
【GPCR】TACR2(NK2R)
Product Center > Cell lines > GPCR
【Others】APJ
Product Center > Cell lines > Others
【Product Center】iPS-Related Plasmids
Product Center > Plasmid
【Cytokines】EPO
Product Center > Cell lines > Cytokines
【TAA】C-MET:HGF
Product Center > Proteins > TAA
【Immunotherapy target】CLEC7A(Dectin-1)
Product Center > Cell lines > Immunotherapy target
【Cytokines】IL-12
Product Center > Proteins > Cytokines
【Cytokines】IL-7
Product Center > Proteins > Cytokines
【Biosimilar Antibodies】Bispecific Antibody
Product Center > Antibodies > Biosimilar Antibodies
【GPCR】LPAR1
Product Center > Cell lines > GPCR
【GPCR】TACR1(NK1R)
Product Center > Cell lines > GPCR
【TAA】CLDN1
Product Center > Cell lines > TAA
【TLR】TLR2
Product Center > Cell lines > TLR
【Product Center】MERS pseudovirus
Product Center > Pseudovirus
【Insights】CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
2024-09-23
【Insights】CD40: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
2024-09-25
【Insights】IL-17: UCB presents new 4-year data for BIMZELX[®](bimekizumab) in moderate to severe plaque psoriasis at EADV 2024
2024-09-25
【Insights】PD-1/VEGF:GlycoMimetics enters into acquisition agreement with Crescent biopharma
2024-11-01
【Insights】CD19/CD20/CD3:GSK enters agreement to acquire CMG1A46 from Chimagen Bioscience
2024-11-01
【Insights】BTK:Sanofi Announces Positive Data from Phase III Study of BTK Inhibitor ITP
2024-11-06
First 16 17 18 19 20 Last
Total 125 Page
Jump
More
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit